News

Novelix Pharmaceuticals Limited, formerly TRIMURT HI LIMITED, submitted a certificate to the BSE Limited under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026, as confirmed by its Registrar and Share Transfer Agent, M/s. Venture Capital and Corporate Investments Private Limited.

Novelix Pharmaceuticals Limited, formerly TRIMURT HI LIMITED, will close its trading window for designated persons and their relatives from Thursday, October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter and half year ended September 30, 2026, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.

Novelix Pharmaceuticals Limited, formerly TRIMURT HI LIMITED, announced the appointment of Mr. Gnana Prakash Gattu as a Whole Time Director for a period of five years, effective August 29, 2026, subject to shareholder approval, according to a filing with the BSE Limited. Mr. Gattu, who is part of the company`s Promoter and Promoter group, holds a degree from IIT-Chennai and has over 25 years of experience in management and information technology.

Novelix Pharmaceuticals Limited, formerly TRIMURT HI LIMITED, will hold a board meeting on Saturday, August 29, 2026, to discuss the notice of its 32nd Annual General Meeting, approve the Board Report for the financial year ended March 31, 2026, appoint a scrutinizer for the AGM and remote e-voting, and consider the appointment of Mr. Gnana Prakash Gattu (DIN:00517921) as Whole Time Director.

Novelix Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 13 August 2026.